Skip to content

Indivior Pharmaceuticals, Inc. INDV Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$175M-10.3%$195M-56.2%$445M-12.7%$510M+37.1%$372M+16.6%
$1.03B+3.0%$995M-0.1%$996M+36.8%$728M+46.2%$498M+98.4%
$21M-34.4%$32M-20.0%$40M-11.1%$45M+25.0%$36M-29.4%
$667M+2.3%$652M-29.3%$922M
$157M+9.0%$144M+16.1%$124M
$2M0.0%$2M0.0%$2M
$1.2B-0.3%$1.2B-15.2%$1.42B
$35M-27.1%$48M+17.1%$41M
$0-100%$29M+61.1%$18M
$779M-14.8%$914M-5.3%$965M
$486M+67.6%$290M-4.6%$304M
$1.34B+3.2%$1.3B-19.9%$1.62B
$0-100%$62M0.0%$62M
-$280M-15.2%-$243M+29.8%-$346M
-$144M-46.9%-$98M+52.7%-$207M+19.5%-$257M+9.8%-$285M+15.4%
$1.2B-0.3%$1.2B-15.2%$1.42B

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Indivior Pharmaceuticals, Inc. cover its short-term obligations?
Its current ratio is 0.86 — current liabilities exceed current assets.
Where does Indivior Pharmaceuticals, Inc. 's balance sheet data come from?
Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.